• June 20, 2013
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a third-quarter dividend payable to holders of the company’s common stock of $0.065 per share. The dividend is to be paid on Sept. 2, 2013, to holders of record on Aug. 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses.more...
  • May 22, 2013
    MADISON, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) announced it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) today in connection with the proposed exchange offer announced by Pfizer Inc. (NYSE: PFE). As part of the offer, Pfizer shareholders will be able to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock. Pfizer currently holds approximately 80% of themore...
  • April 30, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 permore...
  • March 28, 2013
    MADISON, N.J.--(BUSINESS WIRE)--The Board of Directors of ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting itsmore...
  • March 26, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call.Investors and the public may access the live webcast by visiting the Zoetismore...
  • February 6, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing. Zoetis did not receive any of the proceedsmore...
  • August 13, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal healthmore...
  • June 7, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced the next steps in the strategic alternatives review process for the company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (IPO) of a minority ownership stake in the new company. Pfizer expects to provide details regarding the proposed transaction as part of its 2012 second quarter earnings announcement.more...
  • July 7, 2011
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that it is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The company is considering options that may include, among others, a full or partial separation of each of these businesses from Pfizer through a spin-off, sale or other transaction.more...